Literature DB >> 1686137

von Recklinghausen's disease associated with somatostatin-rich duodenal carcinoid (somatostatinoma), medullary thyroid carcinoma and diffuse adrenal medullary hyperplasia.

A Yoshida1, S Hatanaka, Y Ohi, Y Umekita, H Yoshida.   

Abstract

This report describes the concomitant occurrence of a somatostatin-rich duodenal carcinoid, a medullary thyroid carcinoma and a diffuse adrenal medullary hyperplasia in a patient with von Recklinghausen's disease. A 50-year-old Japanese man died from lung metastasis of a malignant schwannoma. In addition to extensive viscero-cutaneous neurofibromatosis, two different types of neuroendocrine tumors were found in the duodenum and thyroid gland at autopsy. The duodenal tumor, which was located in the second portion, showed the histologic appearance of a carcinoid tumor with glandular differentiation and psammoma-bodies. Immunohistochemically the tumor cells were intensely positive for somatostatin. The thyroid tumor was composed of nests of tumor cells arranged in an endocrine pattern, and showed immunoreactivity for calcitonin. A review of the literature revealed no previously reported case of concomitant occurrence of duodenal somatostatinoma and medullary thyroid carcinoma in a single patient with von Recklinghausen's disease. Morphometric analysis of adrenal glands disclosed the presence of diffuse medullary hyperplasia. Thus, the present case exhibited a similarity in some respects with multiple endocrine neoplasia (MEN) syndrome, Type IIa or IIb.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686137     DOI: 10.1111/j.1440-1827.1991.tb01629.x

Source DB:  PubMed          Journal:  Acta Pathol Jpn        ISSN: 0001-6632


  12 in total

Review 1.  Biologics in gastrointestinal and pancreatic neuroendocrine tumors.

Authors:  Iris H Liu; Pamela L Kunz
Journal:  J Gastrointest Oncol       Date:  2017-06

2.  Ampullary somatostatinoma in a patient with von Recklinghausen's disease.

Authors:  O Kainuma; Y Ito; T Taniguchi; T Shimizu; H Nakada; Y Date; T Hara
Journal:  J Gastroenterol       Date:  1996-06       Impact factor: 7.527

Review 3.  Periampullary and duodenal neoplasms in neurofibromatosis type 1: two cases and an updated 20-year review of the literature yielding 76 cases.

Authors:  Daniel Relles; Jennie Baek; Agnieszka Witkiewicz; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2010-03-19       Impact factor: 3.452

Review 4.  [Von Recklinghausen type I neurofibromatosis and neuroendocrine tumor (somatostatinoma) in a 50-year-old woman].

Authors:  M Reichardt; W Rexroth; C Hasslacher
Journal:  Med Klin (Munich)       Date:  1998-09-15

5.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

6.  Report from the 13th annual Western canadian gastrointestinal cancer consensus conference; calgary, alberta; september 8-10, 2011.

Authors:  M M Vickers; J Pasieka; E Dixon; S McEwan; A McKay; D Renouf; D Schellenberg; D Ruether
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

7.  Neurofibromatosis and insulinoma.

Authors:  J W Fung; K S Lam
Journal:  Postgrad Med J       Date:  1995-08       Impact factor: 2.401

8.  Thyroid Gland 18F-FDG Uptake in Neurofibromatosis Type 1.

Authors:  Zoë Y G J van Lierop; Sander Jentjens; Monique H M E Anten; Roel Wierts; Connie T Stumpel; Bas Havekes; Marinus J P G van Kroonenburgh
Journal:  Eur Thyroid J       Date:  2018-06-05

9.  Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors.

Authors:  Kein-Leong Yim
Journal:  Cancer Manag Res       Date:  2012-07-31       Impact factor: 3.989

10.  Population-based study of islet cell carcinoma.

Authors:  James C Yao; Milton P Eisner; Colleen Leary; Cecile Dagohoy; Alexandria Phan; Asif Rashid; Manal Hassan; Douglas B Evans
Journal:  Ann Surg Oncol       Date:  2007-09-26       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.